ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup  randomized phase III clinical trial.

Patrice Carde, Nicolas Mounier, Catherine Fortpied et al.|Journal of Clinical Oncology|2012

Cited by 50